News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as much as ...
Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results